Literature DB >> 8589143

Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus.

F P Kroon1, J T van Dissel, J Labadie, A M van Loon, R van Furth.   

Abstract

A prospective study of antibody production by adults infected with human immunodeficiency virus (HIV) after vaccination with T lymphocyte-dependent diphtheria toxoid, tetanus toxoid, and inactivated trivalent poliovirus vaccine was conducted. Individuals were divided into three groups according to CD4+ T-lymphocyte count: group 1 had a count of < or = 100-300 x 10(6)/L; and group 3, > 300 x 10(6)/L. After vaccination, 61%, 70%, and 73% of the individuals in groups 1, 2, and 3, respectively, developed protective titers of antibody to diphtheria toxin; the mean postvaccination antibody titer of HIV-infected individuals was significantly lower than that of healthy controls not infected with HIV. Furthermore, the mean titers of antibodies to tetanus toxin and poliovirus were significantly lower in HIV-infected individuals with CD4+ lymphocyte counts of < 300 x 10(6)/L than in controls. Of the HIV-infected vaccinees, 83%-100% were protected against tetanus and 78%-100% against polio. We conclude that HIV-infected individuals with CD4+ lymphocyte counts of < 300 x 10(6)/L have an impaired (secondary) antibody response after receipt of T lymphocyte-dependent vaccines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589143     DOI: 10.1093/clinids/21.5.1197

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

Review 1.  Tetanus.

Authors:  J J Farrar; L M Yen; T Cook; N Fairweather; N Binh; J Parry; C M Parry
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

2.  Immunoglobulin G (IgG) subclass distribution and IgG1 avidity of antibodies in human immunodeficiency virus-infected individuals after revaccination with tetanus toxoid.

Authors:  F P Kroon; M J van Tol; C M Jol-van der Zijde; R van Furth; J T van Dissel
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

Review 3.  An immunization update for HIV-infected adults in the United States: review of the literature.

Authors:  Patricia A Cioe; Kathleen Melbourne; Jerome Larkin
Journal:  J Assoc Nurses AIDS Care       Date:  2015 Mar-Apr       Impact factor: 1.354

4.  Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults.

Authors:  Stephanie B Troy; Diana Kouiavskaia; Julia Siik; Efrat Kochba; Hind Beydoun; Olga Mirochnitchenko; Yotam Levin; Nancy Khardori; Konstantin Chumakov; Yvonne Maldonado
Journal:  J Infect Dis       Date:  2015-01-07       Impact factor: 5.226

5.  OPV strains circulation in HIV infected infants after National Immunisation Days in Bangui, Central African Republic.

Authors:  Alexandre Manirakiza; Emmanuella Picard; Richard Ngbale; Didier Menard; Ionela Gouandjika-Vasilache
Journal:  BMC Res Notes       Date:  2010-05-18

Review 6.  Vaccination in HIV-infected adults.

Authors:  Nancy F Crum-Cianflone; Mark R Wallace
Journal:  AIDS Patient Care STDS       Date:  2014-07-16       Impact factor: 5.078

7.  CD4+ levels control the odds of induction of humoral immune responses to tracer doses of therapeutic antibodies.

Authors:  Sharat Srinivasula; Erin Gabriel; Insook Kim; Paula DeGrange; Alexis St Claire; Candace Mallow; Robert E Donahue; Chang Paik; H C Lane; Michele Di Mascio
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

8.  Paralytic poliomyelitis associated with live oral poliomyelitis vaccine in child with HIV infection in Zimbabwe: case report.

Authors:  I Chitsike; R van Furth
Journal:  BMJ       Date:  1999-03-27

Review 9.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

10.  Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: an INITIO substudy.

Authors:  C T Burton; R L Goodall; A Samri; B Autran; A D Kelleher; G Poli; G Pantaleo; F M Gotch; N Imami
Journal:  Clin Exp Immunol       Date:  2008-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.